Literature DB >> 8104947

Comparative analysis of p53 and c-myc expression and cell proliferation in human hepatocellular carcinomas--an enhanced immunohistochemical approach.

M Saegusa1, Y Takano, H Kishimoto, G Wakabayashi, K Nohga, M Okudaira.   

Abstract

Expression of p53 and c-myc was investigated and compared with cell proliferative activity in a series of 40 hepatocellular carcinomas (HCC), by means of enhanced immunohistochemistry. p53 expression was demonstrated in 5 out of 40 HCC (12.5%) with the incidence increasing in 5 out of 40 HCC (12.5%) with the incidence increasing in proportion to the histological grading of malignancy: thus, 0% of well-differentiated, 6.9% of moderately differentiated and 33.3% of poorly differentiated lesions were positive. The proliferating-cell nuclear antigen (PCNA) labeling index also showed a statistically significant increase with this grading. Distribution patterns of PCNA-positive cell were divided into four types: scatter, marginal, mosaic and diffuse. Four HCC cases, predominantly of the poorly differentiated type, exhibited the diffuse pattern. Generally, p53 overexpression corresponded well with PCNA positivity. In contrast, there was no correlation between c-myc overexpression, found in 19 out of 40 HCC (47.5%), and histological grading of HCC or PCNA labeling index. The distribution pattern of c-myc-positive HCC cells was also different from that of PCNA and p53. Our results suggest that p53 overexpression closely relates to proliferation of HCC cells. Furthermore, there may be a consistent difference in regulatory mechanisms between p53 and c-myc expression in multistep hepatocarcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8104947     DOI: 10.1007/bf01195346

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  45 in total

1.  Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression.

Authors:  W E Mercer; M T Shields; D Lin; E Appella; S J Ullrich
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

2.  Regional mapping to 4q32.1 by in situ hybridization of a DNA domain rearranged in human liver cancer.

Authors:  V Blanquet; F Garreau; X Chenivesse; C Brechot; C Turleau
Journal:  Hum Genet       Date:  1988-11       Impact factor: 4.132

3.  Poly(A+)RNA levels of growth-, differentiation- and transformation-associated genes in the progressive development of hepatocellular carcinoma in the rat.

Authors:  B E Huber; C A Heilman; S S Thorgeirsson
Journal:  Hepatology       Date:  1989-05       Impact factor: 17.425

4.  Transient induction of c-jun during hepatic regeneration.

Authors:  J A Alcorn; S P Feitelberg; D A Brenner
Journal:  Hepatology       Date:  1990-06       Impact factor: 17.425

5.  Immunohistochemical demonstration of epidermal growth factor and c-myc oncogene product in normal, benign and malignant thyroid tissues.

Authors:  Y Mizukami; A Nonomura; T Hashimoto; T Michigishi; M Noguchi; F Matsubara; N Yanaihara
Journal:  Histopathology       Date:  1991-01       Impact factor: 5.087

6.  Expression of oncogenes in human liver disease.

Authors:  Y Himeno; Y Fukuda; M Hatanaka; H Imura
Journal:  Liver       Date:  1988-08

7.  Mutational hotspot in the p53 gene in human hepatocellular carcinomas.

Authors:  I C Hsu; R A Metcalf; T Sun; J A Welsh; N J Wang; C C Harris
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

8.  Maintenance of p53 alterations throughout breast cancer progression.

Authors:  A M Davidoff; B J Kerns; J D Iglehart; J R Marks
Journal:  Cancer Res       Date:  1991-05-15       Impact factor: 12.701

Review 9.  Translocations among antibody genes in human cancer.

Authors:  P Leder; J Battey; G Lenoir; C Moulding; W Murphy; H Potter; T Stewart; R Taub
Journal:  Science       Date:  1983-11-18       Impact factor: 47.728

10.  Frequent loss of heterozygosity on chromosomes 16 and 4 in human hepatocellular carcinoma.

Authors:  W D Zhang; S Hirohashi; H Tsuda; Y Shimosato; J Yokota; M Terada; T Sugimura
Journal:  Jpn J Cancer Res       Date:  1990-02
View more
  6 in total

1.  Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications.

Authors:  P C Wu; J W Fang; V K Lau; C L Lai; C K Lo; J Y Lau
Journal:  Am J Pathol       Date:  1996-10       Impact factor: 4.307

2.  In situ characterization of inflammatory responses in the rectal mucosae of patients with shigellosis.

Authors:  D Islam; B Veress; P K Bardhan; A A Lindberg; B Christensson
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

3.  The significance of p53 mutations as an indicator of the biological behavior of recurrent hepatocellular carcinomas.

Authors:  H Sugo; S Takamori; K Kojima; T Beppu; S Futagawa
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

4.  Is p53 gene mutation an indicatior of the biological behaviors of recurrence of hepatocellular carcinoma?

Authors:  I-Shyan Sheen; Kuo-Shyang Jeng; Ju-Yann Wu
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

5.  p53 expression in normal and dysplastic bronchial epithelium and in lung carcinomas.

Authors:  C Walker; L J Robertson; M W Myskow; N Pendleton; G R Dixon
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640

6.  Molecular Signatures of Recurrent Hepatocellular Carcinoma Secondary to Hepatitis C Virus following Liver Transplantation.

Authors:  Trina Das; Deborah L Diamond; Matthew Yeh; Sajida Hassan; Janine T Bryan; Jorge D Reyes; James D Perkins
Journal:  J Transplant       Date:  2013-11-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.